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In the past, chemotherapy of renal adenocarcinoma has 
been relatively unsuccessful. The progestational agent, 
medroxy progesterone acetate (MPA), has been the most 
effective single agent, even though the response rate prob-
ably does not exceed 12%. This report describes the results 
of a program of combination therapy with MPA, cyclo-
phosphamide, hydroxyurea, vinblastine and prednisone 
that was used on 42 patients, ten of whom had received prior 
MPA therapy. One complete remission and seven partial 
remissions were observed, oniyone of whom had received 
prior MPA therapy. Treatment of metastatic renal adenocar-
cinoma with combination chemotherapy should probably 
include MPA and adriamycin. The role of estrogen receptor 
(ER) and progesterone receptor (PR) as predictions of re-
sponse to hormonal therapy in this disease looks encourag-
ing, but the results reported to date have been limited. 
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Renal adenocarcinoma is one of the malignancies most 
resistantto control with systemic chemotherapy. Bloom and 
Wallace^ in 1964 were the first to report that progestational 
steroids and androgenic steroids have a definite palliative 
effect in metastatic renal carcinoma. This treatment was 
based on experimental evidence of Bloom et aP who used 
androgens and progestins to block estrogen-induced renal 
carcinoma in hamsters. Our initial experience with these 
hormonal agents at Henry Ford Hospital was first reported in 
1969^ and subsequently updated in 1973." Of the several 
chemotherapeutic agents we tested, only vinblastine had 
any effect, as noted in two of 15 patients. However, a 
summary of the literature before 1972 suggested that an 
approximate 20% response rate has been reported with 
cyclophosphamide, hydroxyurea and vinblastine." Since 
then, only the nitrosourea, CCNU, has seemed efficacious* 
in treating renal carcinoma. Other studies have not been as 
encouraging.* 
Many of the newer chemotherapeutic agents, including 
adriamycin,^ cis platinum,* and chlorozotocin,^ have had 
trials as single drugs in metastatic renal adenocarcinoma, 
but no significant-responses have been reported. 
A variety of programs of combination chemotherapy have 
been reported, and a limited review of some are as follows: 
1) MPA, BCG, adriamycin and vincristine (10/31)^° 
2) Methylprednisolone, CCNU, bleomycin (1/16)" 
3) Methy lpredniso lone, C C N U , b leomycin and 
adriamycin (3/14)" 
4) MPA, adriamycin, hydroxyurea and vinblastine (4/8)''^ 
5) Testosterone, MPA, vincristine, actinomycin D and 
cyclophosphamide (0/4)''^ 
It is apparent from this that adriamycin and MPA are among 
the more active of these combinations. Recent studies in 
passive and active immunotherapy are in progress, but it is 
too early to include their results in this partial review. The 
progestational steroid, medroxyprogesterone acetate (MPA), 
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has had extensive trials, and no significant toxicity is 
associated with its use. However, the response rate probably 
does not exceed 12%. Studies of estrogen receptor (ER) and 
progesterone receptor (PR)of kidney carcinoma suggestthat 
the response rates to hormonal therapy in patients with 
positive ER and PR are higher than in patients with negative 
receptors. Of the five complete responses reported by our 
institution,*'" three are still al ive without evident disease and 
one died of unrelated causes. All of the surviving patients 
have had a 10-1- year survival. Only one of the patients 
classftied as a complete response to MPA has had a recur-
rence. All who experienced a partial or complete response 
had undergone a nephrectomy either at, or prior to, the time 
metastatic disease was diagnosed. 
Methods 
This report reviews our experience with a program of 
combinat ion therapy consist ing of MPA, vinblast ine, 
cyclophosphamide, hydroxyurea and prednisone. The dos-
age schema is given in Table I. Forty-two patients were 
entered on the study. Ten had received prior progestional 
and/or androgenic therapy. Patients were entered on the 
study only ft they had a predicted survival of at least eight 
weeks. All patients received at least two courses and were 
followed fora minimum of eight weeks. 
Responses were evaluated as follows: 
1. Patients were classified as complete responses if all 
evidence of measurable disease cleared for at least three 
months. 
2. A partial response was declared if there was a 50% or 
moredecrease in the diameters of all measurable lesions. 
3. Either no change or a stable disease classification was 
used if the response was less than partial or the lesions 
did not appear to change for six months or longer. 
4. A failure was defined if any new lesions developed or ft 
there was an increase in the size of preexisting lesions by 
25% or more. 
T A B L E 1 
Combination Chemotfierapy S c h e m a 
Drug Dosage 
Cyclophosptiamide 
Vinblastine 
Hydroxyurea 
Med roxyprogestrone 
acetate 
Prednisone 
400 mg/M^ day 1 IV 
3 mg/M= days 1 and 2 IV 
500 mg / days 8 to 28 orally 
1,000 mg q-wk Ilui x 4 wks, ttien 400 mg/wk 
50 mg/M^ po. q-d 
Results 
As recorded in Table II, the combination program has 
produced only one complete response and seven partial 
responses. These responses are disappointing in that the 
response rate is not better than that observed with MPA 
therapy alone when all 42 patients are included. Of the 
patients who had received prior MPA treatment, only one of 
ten, or 10%, responded to this combination program. This 
patient had had a partial response to MPA therapy, whereas 
none of the others had responded to MPA therapy at all. 
However, in seven of 32 patients (21.8%) who had not 
received prior MPA, there was one complete response and 
six partial responses. This may be considered some im-
provement over MPA therapy alone; however, the dif-
ference is not significant by the X^ method of analysis 
(p>0.05). The comparison was with historical MPA controls 
as previously reported." The significance of the stable 
disease category (Table II) is difficult to interpret because of 
the variable nature of the disease. However, the survival 
statistics for these patients are definitely better than those for 
patients classified as fail ures to therapy. The one patient who 
responded completely is alive and has no measurable 
disease42 months after therapy began. The median survival 
of the seven patients classified as partial responses is 18 
months. Partial responses have been observed primarily in 
lung and subcutaneous metastases. However, in one patient 
with lytic osseous metastases to the skull healing of these 
lesions has been observed after ten months of therapy. In 
patients with stable disease, three had osseous metastases 
and four had only soft-tissue metastases. The current study 
employing five agents (MPA, vinblastine, cyclophospha-
mide, hydroxyurea and prednisone) did not show a signifi-
cant improvement in response over MPA alone. For patients 
in the no change or stable category, median survival was 12 
months; for those who failed to respond to therapy, median 
survival was 5 months. 
TABLE l l 
Response to Combination Chemotfierapy 
Patients (42) Complete Partial Stable Failure Total 
Prior MPA Ttierapy (10) 0 1 9 10 
No Prior MPA Ttierapy (32) 1 6 7 18 32 
Combination Program Totals 1 7 7 27 42 
Discussion 
Metastatic adenocarcinoma of the kidney is a slowly pro-
gressive, relentless disease. Attempts to halt its course with 
combination chemotherapy have not met with great suc-
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cess, and progestational agent therapy continues to be the 
mainstay ofany program. If possible, removal ofthe primary 
renal neoplasm appears to be important in effecting any 
control over the metastases."'" Other combinations of 
chemotherapeutic agents have been attempted, and some of 
these are reviewed. Apparently, inc lud ing MP,^ and 
adriamycin in any combination may improve the response 
rate. 
adriamycin. The use of MPA for patients with a high risk of 
recurrence should be considered as adjuvant to nephrec-
tomy in cases of renal adenocarcinoma, especially in those 
patients with extension through the renal capsule or exten-
sion into the renal vein. Further evaluation of ER and PR is 
necessary to determine ifthese studies wil l be predictive of 
hormonal response. 
Conclusion 
We recommend further exploration of other combinations 
of drugs which at this time should include MPA and 
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